Tags : Atherosclerotic Cardiovascular Disease

Merck and Pfizer Report Results of Steglatro (ertugliflozin) in P-III VERTIS CV Study for Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Clinical Trials Pharma

Merck and Pfizer Report Results of Steglatro (ertugliflozin) in P-III

Tuba Khan June 17, 2020

Shots: The P-III VETRIS CV study evaluates the Steglatro (5mg, 15mg) vs PBO in addition to SOC as background treatment in 8,200+ patients with T2D and atherosclerotic CV disease across […]readmore

Copyright © 2020 Digiqole. All Right Reserved.